199 results on '"Boussioutas, Alex"'
Search Results
2. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions
3. Premalignant lesions of the stomach and management of early neoplastic lesions
4. Contributors
5. Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention
6. Supplementary Tables from DNA Methylation in Peripheral Blood and Risk of Gastric Cancer: A Prospective Nested Case–control Study
7. Figure S5 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
8. Figure S7 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
9. Figure S2 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
10. Table S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
11. Table S2 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
12. Figure S4 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
13. Figure S3 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
14. Data from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
15. Figure S6 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
16. Figure S5 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
17. Table S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
18. Figure S4 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
19. Data from DNA Methylation in Peripheral Blood and Risk of Gastric Cancer: A Prospective Nested Case–control Study
20. Supplementary Tables from DNA Methylation in Peripheral Blood and Risk of Gastric Cancer: A Prospective Nested Case–control Study
21. Table S2 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
22. Data from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
23. Data from DNA Methylation in Peripheral Blood and Risk of Gastric Cancer: A Prospective Nested Case–control Study
24. Table S3 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
25. Figure S6 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
26. Figure S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
27. Figure S2 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
28. Figure S1 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
29. Can butyrate prevent colon cancer? The AusFAP study: A randomised, crossover clinical trial
30. Supplementary Table 2 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
31. Supplementary Table 4 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
32. Supplementary Table 2 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
33. Supplementary Table 5 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
34. Supp Legends and Table S1 and S2 from Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations
35. Data from Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations
36. Supplementary Table 1 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
37. Fig S7 from Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations
38. Data from Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations
39. Supplementary Materials and Methods from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
40. Fig S5 from Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations
41. Supplementary Table 8 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
42. Supplementary Table 6 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
43. Supplementary Table 8 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
44. Supplementary Table 3 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
45. Supplementary Table 7 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
46. Supplementary Materials and Methods from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
47. Supplementary Table 3 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
48. Supplementary Table 4 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
49. Supplementary Material from Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer
50. Supplementary Material from Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.